Pravastatin vs Fluvastatin — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

HMG-CoA Reductase Inhibitor (Statin)

Pravastatin

First FDA approval: 2006-04-25

HMG-CoA Reductase Inhibitor (Statin)

Fluvastatin

Brand: Lescol

First FDA approval: 2000-10-06

Lowest NADACAcquisition cost floor across all NDCs

$0.060Per unit

$2.54Per unit

Average NADACAcross all dosage forms and strengths

$0.085Up to $0.150

$3.47Up to $13.06

Generic manufacturersActive ANDA holders — FDA Orange Book

1247 total ANDAs filed

36 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$188.5MFull year

$10.7MFull year

Part D claims (CY24)Total fills, all strengths

13.9M4.4M beneficiaries

59K20K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$14Per claim, all NDCs

$182Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

54Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

DiscontinuedSee drug profile

Generic availableFDA Orange Book

Yes12 manufacturers

Yes3 manufacturers